1 – 10 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hematological and renal toxicity in mice after three cycles of high activity [177Lu]Lu-PSMA-617 with or without human α1-microglobulin
(
- Contribution to journal › Article
- 2023
-
Mark
Tumor Control Probability and Small-Scale Monte Carlo Dosimetry : Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy
(
- Contribution to journal › Article
- 2022
-
Mark
Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617
(
- Contribution to journal › Article
-
Mark
Small-scale dosimetry for alpha particle 241Am source cell irradiation and estimation of γ-H2AX foci distribution in prostate cancer cell line PC3
(
- Contribution to journal › Article
- 2021
-
Mark
Humanization, radiolabeling and biodistribution studies of an igg1-type antibody targeting uncomplexed psa for theranostic applications
(
- Contribution to journal › Article
-
Mark
Kidney protection with the radical scavenger α1-microglobulin (A1m) during peptide receptor radionuclide and radioligand therapy
(
- Contribution to journal › Article
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
(
- Contribution to journal › Article
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
(
- Contribution to journal › Article
- 2019
-
Mark
Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics
(
- Contribution to journal › Article
- 2018
-
Mark
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
(
- Contribution to journal › Article